868 abstracts found.



Results filter

A patient RCC-derived murine xenograft model allows better prediction of treatment responses to molecular targeted therapy in patients with advanced renal cancer

Year:

Session type:

Mei Yi Sim1, Hong Gee Sim1, Tsung Wen Chong1, Weber Lau1, Christopher Cheng1, Hung Huynh2, John SP Yuen1

1Singapore General Hospital, Singapore, 2National Cancer Centre, Singapore, Singapore

Sequence-dependent strategies for the optimisation of combinations of PI3K pathway inhibitors and classical anticancer agents

Year:

Session type:

Marco Mazzoletti, Massimo Broggini

Mario Negri Institute, Milan, Italy

Expression of Eag1 and HERG potassium channels in ovarian cancer

Year:

Session type:

Viren Asher1, Raheela Khan1, Heidi Sowter3, Robert Shaw1, Anish Bali2

1School of Graduate Entry Medicine and Health Sciences, Derby, UK, 2Derby Hospitals NHS Trust, Derby, UK, 3University of Derby, UK

Cytotoxicity of a protodioscin rich fraction from fenugreek seeds against human cancer cell lines

Year:

Session type:

Vikram Gota1, Aarti Juvekar1, Parikshit Bansal2

1ACTREC, Tata Memorial Centre, Navi Mumbai, Maharastra, India, 2National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India

Combining inhibitors of the mTOR (AZD8055) and MEK1/2 (AZD6244; ARRY-142886) pathways demonstrates enhanced apoptotic signalling and tumour growth inhibition in human tumour xenograft models

Year:

Session type:

Sarah Holt2, Nicola Curtis1, Armelle Logie1, Patrizia Sini1, Barry Davies1, Christine Chresta1, Sylvie Guichard1, Paul Smith1, Robert Wilkinson1

1AstraZeneca, Alderley Edge, UK, 2Paterson Institute for Cancer Research, Manchester, UK

Identification of novel STAT3 inhibitors

Year:

Session type:

B.Piku Basu1, Giovanna Zinzalla1, Rashedul Haque1, Dyeison Antonow1, Andy Wilderspin1, Fyeza Hasan2, Daniel Morgenstern2, John Anderson2, David E. Thurston1

1The School of Pharmacy, University of London, UK, 2The Institute of Child Health, London, UK

Induction of thrombospondin-1 mediates the anti-angiogenic activity of dexrazoxane

Year:

Session type:

Stephanie Maloney1, Dianne Sullivan2, Steven Suchting2, Jonathan Barker3, Sudha Sundar4, Roy Bicknell1

1Institute for Biomedical Research, University of Birmingham, UK, 2Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK, 3St Johns Institute of Dermatology, Kings College London, UK, 4School of Cancer Sciences, University of Birmingham, UK

Comparing the immune response to radiation-induced tumour cell death with pure apoptosis using a Doxycycline-dependent caspase 3 death switch model

Year:

Session type:

M Melis1, K Simpson1, J Honeychurch1, A Welman1, M MacFarlane2, C Dive1, T Illidge1

1Paterson Institute for Cancer Research, University of Manchester, UK, 2MRC Toxicology Centre, Leicester, UK

Effect of anti-CTLA4 (tremelimumab) on the immunomodulatory activity of t regulatory cells

Year:

Session type:

Sameena Khan, Debbie Burt, Christy Ralph, Robert Hawkins, Eyad Elkord

Paterson Institute for Cancer Research, University of Manchester, UK

Rho-GTPase signaling and the vascular disrupting activities of combretastatin A-4-phosphate

Year:

Session type:

Chryso Kanthou, Leigh Williams, Gillian Tozer

University of Sheffield, UK

Homologous recombination and ovarian cancer: role of developing a functional assay

Year:

Session type:

Asima Mukhopadhyay, Yvette Drew, Evan Mulligan, Sarah Wilkinson, Suzanne Kyle, Ahmed Elatter, Nicola Curtin, Richard Edmondson

Northern Institute for Cancer Research, Newcastle University, UK

Novel anticancer drug combinations exploiting arginine depletion with ADI-PEG 20 in the treatment of ASS1-negative malignant mesothelioma

Year:

Session type:

Barbara Delage1, Claude Chelala1, Dean Fennell2, Nick Lemoine1, Peter Szlosarek1

1Institute of Cancer, Barts and The London, London, UK, 2Centre for Cancer Research and Cell Biology, Belfast, UK

Use of Green Fluorescent Protein (GFP)-imaging to visualise in vivo responses to the anti-tumour agent TRAIL

Year:

Session type:

Neil Cross1, Anne Fowles2, Jenny Lippitt2, Srdjan Hamdy2, Freddie Vitovski2, Colby Eaton2

1Sheffield Hallam University, Sheffield, UK, 2University of Sheffield, UK

A community collaborative approach to promote the earlier presentation and diagnosis of cancer

Year:

Session type:

Becky Whiteman, Peter Handslip, Danielle Taylor

Arden Cancer Network, Coventry, UK

A systematic review of interventions to increase cancer awareness and promote early presentation

Year:

Session type:

Lindsay Forbes1, Louise Atkins1, Joan Austoker2, Clare Bankhead2, Faith Martin2, Kathryn Robb3, Jane Wardle3, Amanda Ramirez1

1King's College London, UK, 2University of Oxford, UK, 3University College London, UK

Does paclitaxel chemotherapy cause long-term arthralgia? Results of a focussed questionnaire in ovarian cancer patients on follow-up

Year:

Session type:

Naomi Lock, Charlie Gourley, Morven Shipway, Tzyvia Rye, Moira Stewart, Melanie Mackean

University of Edinburgh, UK

Engineering and characterisation of a b aculovirus-expressed m ouse/ human chimeric antibody against transferrin receptor on the surface of human tumour cells

Year:

Session type:

Xin Shen, Gui-bin Hu, Guan-xin Shen

Hubei University of Chinese Medicine, Wuhan City, China

Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumour activity, both alone and in combination with VEGF inhibitors, in a panel of tumour xenograft models

Year:

Session type:

David Blakey1, Steve Emery1, Joe Zhou2, Jane Kendrew1, Corinne Reimer3, Alex Cao3, Andy Ryan1, Juliane Jrgensmeier1, Jeff Brown3

1AstraZeneca, Alderley Park, Macclesfield, UK, 2Abgenix Inc., Fremont, California, USA, 3AstraZeneca, GateHouse Park, Waltham, USA

Mustard blood partition: differences between rodents and cancer patients, and the consequences for anticancer drug development

Year:

Session type:

Martin Highley1, Hans Prenen2, Zidang Zang2, Ernst De Bruijn2

1Plymouth Oncology Centre, Derriford Hospital, Plymouth, UK, 2Laboratory of Experimental Oncology, University of Leuven, Belgium

Development of allo-restricted cytotoxic T cell specific for TWIST a potential novel target for cancer immunotherapy of childhood cancers

Year:

Session type:

Edmund Poon, Meng-yong Yan, Nourredine Himoudi, Rebecca Wallace, Persis Amrolia, John Anderson

University College London Institute of Child Health & Great Ormond Street Hospital, London, UK

High-throughput screen for small molecule inhibitors of DNA mismatch repair

Year:

Session type:

Nicholas Pedley, Cecilia Lundin, Daniel Ebner, Thomas Helleday

University of Oxford, UK

Development of human apurinic/apyrimidinic endonuclease (APE1) inhibitors for cancer therapy

Year:

Session type:

Mohammed Mohammed, Charles Laughton, Lodewijk Dekker, Peter Fischer, Rachel Abbots,Poulam Patel, Madhusudan Srinivasan

University of Nottingham, UK

Identification and characterisation of small molecule inhibitors of phosphatidylinositol-4-phosphate 5-kinase

Year:

Session type:

Sylvie Lachmann1, Sarah Griffiths1, Oliver Kern1, James Smith1, Tracey Hunter1, Mar Jimenez Quesada1, Laura Bill1, Jon Roffey1, Elisabeth Trivier1, Robert Wood1, Ai Ching Wong1, Louise Tonkin1, Marc Pittman1, Leon Pang1, Tim Hammonds1, Caroline Foxton1, David R Jones2, Nullin Divecha2, Martin Swarbrick1, Iris Treinies1

1Cancer Research Technology Discovery Laboratories, London, UK, 2Inositide Laboratory, Paterson Institute for Cancer Research, Manchester, UK

Small molecule inhibitors of the transmembrane receptor tyrosine kinase Axl as potential anti-cancer therapeutics

Year:

Session type:

Azadeh Bagherzadeh1, Neil Jones1, Michelle Barnard1, Alexandra Boakes1, Timo Heikkila1, James Firth1, Gregoire Pave1, Emma Wynne1, Francesca Blum1, Irene Farr Gutierrez1, Kevin Stewart1, Aurore Lejeune1, Tim Hammonds1, Alan Storey3, Edel OToole2, Lorna Stewart1, Laurent Rigoreau1

1Cancer Research Technology Discovery Lab, London, UK, 2Barts and London School of Medicine and Dentistry, Queen Mary, University of London, UK, 3Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK

Pharmacokinetic and pharmacodynamic phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition

Year:

Session type:

Shahneen Sandhu1, Tim Yap1, Nina Tunariu1, Martyn Lolkema1, Daniel Tan1, Andre Brunetto1, Rebecca Kristeleit1, Salma Alam1, L. Rhoda Molife1, Joyce Kapawa1, Michael Germuska2, Edward Garmey3, Feng Chai3, James Li3, Stan B. Kaye1, Nandita deSouza1, Johann S. de Bono1

1 Royal Marsden NHS Foundation Trust, Sutton, UK, 2The Institute of Cancer Research, Drug Development Unit, Sutton, UK, 3ArQule Inc, Woburn, Massachusetts, USA

A first in human phase I study of JNJ26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumours: early evidence of anti-tumour activity

Year:

Session type:

AT Brunetto1, R Kristeleit1, D Tan1, T Yap1, S Alam1, S Dolly1, D Olmos1, P Fong1, R Molife1, T Harris1, L Van Besterveldt2, N Fourneau2, P Hellemans2, J De-Bono1, B Venugopal3, J Evans3

1 Royal Marsden Hospital, London, UK, 2Johnson & Johnson Pharmaceuticals, Beerse, Belgium, 3The Beatson Institute, Glasgow, UK

Safety and feasibility of serial tumour biopsies in phase I clinical trials: the Royal Marsden Hospital Drug Development Unit experience

Year:

Session type:

Debashis Sarker, Daniel Tan, Andre Brunetto, Sophia Frentzas, Christina Messiou, Nina Tunariu, Nimrat Mangat, Sarah Stapleton, Nandita Desouza, Jorge Barriuso, Johann de Bono

Royal Marsden Hospital, Sutton, UK

Rationally designed bifunctional bisphosphonates for the detection and radionuclide therapy of bone metastases

Year:

Session type:

Rafael Torres Martin de Rosales1, Ciara Finucane2, Steven J Mather2, Philip J Blower1

1King's College London, UK, 2Institute of Cancer, Barts and The London School of Medicine, UK

A phase-I study of the combination of intravenous reovirus (REOLYSIN ) and gemcitabine in patients with advanced cancer

Year:

Session type:

Daniel Tan1, Martijn Lolkema1, Kevin Harrington2, Martin Forster1, Jeff Evans1, Hendrik-Tobias Arkenau1, Patricia Roxburgh3, Rosie Morrison3, Joyce Kapawa1, Victoria Roulstone3, Matt Coffey3, Salma Alam1, Andre Brunetto1, Timothy Yap1, Karl Mettinger4, Johann de Bono1

1Royal Marsden Hospital, Sutton, UK, 2Cancer Research UK Targeted Therapy Laboratory, Chester Beatty Laboratories, Institute of Cancer Research, London, UK, 3Beatson West of Scotland Cancer Centre, Glasgow, UK, 4Oncolytics Biotech Inc., Calgary, Canada

PAX3 function in embryonic cell lines undergoing different differentiation pathways and their corresponding tumours

Year:

Session type:

Patricia Kumar

Manchester Metropolitan University, UK

A template for development of a policy for access to data and/or biological samples

Year:

Session type:

Michael Chapman2, Karen Groot1, Chris Carrigan2, Brian Clark3, Jane Cope1, William Lowrance4

1National Cancer Research Institute, London, UK, 2National Cancer Intelligence Network, London, UK, 3onCore UK, London, UK, 4Independent Consultant, La Grande Motte, France

Development of core outcomes sets to be reported in clinical trials for curative treatment of upper gastrointestinal cancer: a systematic review of the literature

Year:

Session type:

Angus McNair1, Thomas Crosby2, Michael Griffin3, Jane Blazeby1

1University of Bristol, UK, 2Velindre Cancer Centre, Cardiff, UK, 3Royal Victoria Infirmary, Newcastle, UK

The efficacy of MEK-inhibitor treatment of B-Raf mutant tumours requires Bim and is enhanced by the BH3-mimetic ABT-737

Year:

Session type:

Mark Cragg1, Elisa Jansen2, Michelle Cook2, Claire Harris1, Andreas Strasser2, Clare Scott2

1Southampton University School of Medicine, UK, 2Walter and Eliza Hall Institute, Melbourne, Australia

Loss of a FOX03A-dependent cell cycle checkpoint for DNA replication origins s ensitises cancer cells to CDC7 inhibitors

Year:

Session type:

Slavica Tudzarova, Matthew Trotter, Claire Mulvey, Jasminka Godovac-Zimmermann, Kai Stoeber, Gareth Williams

University College London, UK

A fully human antibody that inhibits the integrin avb6 reduces tumour growth and modulates key biomarkers

Year:

Session type:

Cath Eberlein1, Ian Foltz2, Avril Alfred2, Zhu Cao1, Neil Smith1, Viv Jacobs1, Jaspal Kang2, Steve Powell1, Karen McDaid1, Jane Kendrew1, Simon Barry1

1AstraZeneca, Cheshire, UK, 2Amgen, Vancouver, Canada

Clinical outcomes in poor performance patients with advanced ovarian and primary peritoneal cancers

Year:

Session type:

Laura Horsley, Charlie Gourley, Moira Stewart, Tzyvia Rye, Melanie Mackean

Edinburgh Cancer Centre, UK

A comparison of three sources of information to guide the Bayesian design of a trial in the rare cancer Merkel-cell carcinoma

Year:

Session type:

Mark Pritchard1, Lucinda Billingham1, Jeremy Marsden2, Neil Steven1

1Cancer Research UK Clinical Trials Unit, University of Birmingham, UK, 2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

A phase II study of NY-ESO-1 ISCOMATRIX vaccine and NY-ESO-1 ISCOMATRIX vaccine followed by recombinant fowlpox NY-ESO-1 (rF-NY-ESO-1) in patients with high-risk, resected melanoma

Year:

Session type:

Ji-Li Chen1, Sarah Pratap5, Ioannis Karydis5, Andrea Tarlton1, Amina Dawoodji1, Martha Woodward2, Paul Nathan4, Christian Ottensmeier3, Mark Middleton2, Vincenzo Cerundolo1

1Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK, 2Churchill Hospital, Oxford, UK, 3University of Southampton School of Medicine, UK, 4Mount Vernon Hospital, Northwood, UK, 5Churchill Hospital and Tumour Immunology Unit, University of Oxford, UK

Should all patients receiving capecitabine be screened for hypertrigylceridaemia? A prospective audit of incidence and severity

Year:

Session type:

Caroline Michie1, Maria Sakala1, Iain Rivans1, Mark Strachan2, Sally Clive1

1Edinburgh Cancer Centre, Western General Hospital, UK, 2Western General Hospital, Edinburgh, UK

A trial of continuous low dose chemotherapy combined with celecoxib for patients with advanced cancer

Year:

Session type:

Omar Khan1, Andrew Blann2, Miranda Payne1, Mark Middleton1, Andrew Protheroe1, Denis Talbot1, Oksana Kirichek1, Marian Taylor1, Cheng Han1, Adrian Harris1

1University of Oxford, UK, 2University of Birmingham, UK

Evidence that hexa histidine tags on therapeutic proteins are not immunogenic in patients

Year:

Session type:

Surinder Sharma1, Natalie Griffin1, Steve Cleverley2, Hassan Shahbakhti1, Heide Kogelberg1, Berend Tolner1, Richard Begent1, Kerry Chester1

1University College London Cancer Institute, London, UK, 2TouchDown Bioinnovation, Bemmel, Netherlands

Challenges of identifying cancer patients for randomised controlled trials (RCTs) from urology clinics: what lessons can we learn from SPARE? (CRUK/07/011)

Year:

Session type:

Rebecca Lewis1, Robert Huddart1, Alison Birtle2, Jane Blazeby3, Emma Jones1, Emma Hall1, behalf of SPARE TMG1

1The Institute of Cancer Research, Sutton, UK, 2Lancashire Teaching Hospitals, Preston, UK, 3University of Bristol, UK

A retrospective study demonstrating improvement in 5-year and post-relapse survival in ovarian cancer patients over a 24-year period

Year:

Session type:

Katharine Herbert, Tzyvia Rye, Paul Mitchell, Moira Stewart, Melanie Mackean, Charlie Gourley

University of Edinburgh Cancer Research Centre, UK

A Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide) intravenously (IV) every 3 weeks

Year:

Session type:

Emma Cattell1, Debashis Sarker3, Diana Anderson3, Victoria Spanswick4, Scott Davies2, R Agarwal3, Nicki Heywood1, David Kerr2, Ian Judson3, John Hartley4, Mark Middleton1

1Churchill Hospital, Oxford, UK, 2University of Oxford, UK,3Royal Marsden Hospital, Sutton, UK, 4University College London, UK

Maintenance therapy following chemotherapy of relapsed ovarian cancer: a randomised placebo-controlled phase II trial with the angiogenesis inhibitor BIBF 1120

Year:

Session type:

Gordon Rustin1, Jonathan Ledermann2, Alan Hackshaw3, Stan Kaye4, Gordon Jayson5, Hani Gabra6, Lindsey James3, Susan Bell7, Graham Temple7

1Mount Vernon Cancer Centre, Northwood, Middlesex, UK, 2University College London Hospitals, UK, 3CR-UK & University College London Cancer Trials Centre, UK, 4Royal Marsden Hospital, London, UK, 5Christie Hospital, London, UK, 6Hammersmith Hospital, London, UK, 7Boehringer Ingelheim Ltd, Bracknell, UK

Final results of a phase I study of the Heat Shock Protein 90 inhibitor Alvespimycin (17-DMAG) in patients with advanced, solid tumours

Year:

Session type:

Simon Pacey1, Richard Wilson4, Mike Walton1, Martin Eatock4, Anna Zetterlund1, Hendrik-Tobias Arkenau2, Belle Roels3, Florence Raynaud1, Jooern Ang2, Samantha Costigan1, David Olmos2, Rebecca Gallagher4, Paul Workman1, Ian Judson1

1The Institute of Cancer Research, Sutton, UK, 2The Royal Marsden Hospital, Sutton, UK, 3Cancer Research UK, London, UK, 4N. Ireland Cancer Clinical Trials Unit, Belfast, UK

Preliminary activity in adrenocortical tumour (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumours

Year:

Session type:

S Alam1, C Carden1, M Langham2, S Frentzas1, S Dolly1, S Sandhu1, R Kristeleit1, T Yap1, I Casamayor1, T Matthews1, AW Stephens3, S Poondru3, E Kim2, SB Kaye.1

1Institute of Cancer Research, Royal Marsden Hospital, London, UK, 2MD Anderson Cancer Centre, Texas, USA, 3OSI Pharmaceuticals, Colorado, USA

Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study

Year:

Session type:

Martin Forster1, David Olmos1, Sophia Frentzas1, Shahneen Sandhu1, Tim Yap1, Daniel Tan1, Jorge Barriuso1, Michelle Wright1, Morris Groves2, David Reardon3, Martin Curtis4, Jeffrey Hodge4, Ben Suttle4, B Ma4, Joanne Lager4, Johann de Bono1

1Royal Marsden Hospital, Sutton, UK, 2M.D. Anderson, Houston, Texas, USA, 3Duke University Medical Centre, Durham, USA, 4GlaxoSmithKline, Research Triangle Park, USA

A first-in-man, dose-escalating Phase I study of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor in patients with advanced solid tumours

Year:

Session type:

Rebecca Kristeleit1, Andre Brunetto1, David Olmos1, Ann Parker1, Joo-Ern Ang1, Shahneen Sandhu1, Craig Carden1, Rhoda Molife1, Bernd Hentsch2, A Mais2, B Hauns2, Johann De-Bono1

1Royal Marsden Hospital, Sutton, UK, 24SC AG, Planegg-Martinsreid, Germany

Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy

Year:

Session type:

Wolfgang Link, Amancio Carnero, Fabian Zanells

Spanish National Cancer Centre (CNIO), Madrid, Spain